261 Recruiting Acute Myeloid Leukemia Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Top Recruiting Acute Myeloid Leukemia Studies
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS
📍 H Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
View Study & Checklist ➔ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
📍 Levine Cancer Insitute — Charlotte, North Carolina
View Study & Checklist ➔Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
📍 Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
📍 Mayo Clinic - Phoenix — Phoenix, Arizona
View Study & Checklist ➔Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
📍 Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
View Study & Checklist ➔Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
📍 City of Hope National Medical Center — Duarte, California
View Study & Checklist ➔Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
📍 Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM) — The Bronx, New York
View Study & Checklist ➔Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 Children's Hospital of Central California — Madera, California
View Study & Checklist ➔A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
📍 Brigham and Women's Hospital — Boston, Massachusetts
View Study & Checklist ➔Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
📍 University of Colorado — Aurora, Colorado
View Study & Checklist ➔UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
📍 Texas Children's Cancer and Hematology Center — Houston, Texas
View Study & Checklist ➔Revumenib in Combination With 7+3 + Midostaurin in AML
📍 Yale Cancer Center — New Haven, Connecticut
View Study & Checklist ➔Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
📍 MD Anderson — Houston, Texas
View Study & Checklist ➔Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
📍 Illinois CancerCare-Bloomington — Bloomington, Illinois
View Study & Checklist ➔Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
📍 Masonic Cancer Center — Minneapolis, Minnesota
View Study & Checklist ➔Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
View Study & Checklist ➔Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
📍 Stony Brook Cancer Center — Stony Brook, New York
View Study & Checklist ➔National Cancer Institute "Cancer Moonshot Biobank"
📍 Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis — Daphne, Alabama
View Study & Checklist ➔IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
📍 City of Hope National Medical Center /ID# 269273 — Duarte, California
View Study & Checklist ➔Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
📍 City of Hope — Duarte, California
View Study & Checklist ➔Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
View Study & Checklist ➔Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
📍 Banner University Medical Center - Tucson — Tucson, Arizona
View Study & Checklist ➔Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
📍 Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
View Study & Checklist ➔Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
📍 City of Hope Medical Center — Duarte, California
View Study & Checklist ➔ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
📍 M D Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia
📍 University of Rochester Medicine — Rochester, New York
View Study & Checklist ➔